A Phase 1 Trial of MK-2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole Plus Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive Metastatic Breast Cancer
Phase of Trial: Phase I
Latest Information Update: 30 Jul 2018
At a glance
- Drugs MK 2206 (Primary) ; Anastrozole; Fulvestrant
- Indications Advanced breast cancer
- Focus Adverse reactions
- 20 Jul 2018 Status changed from active, no longer recruiting to completed.
- 10 Jun 2017 Biomarkers information updated
- 03 Jun 2014 Results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.